Online-Only Supplementary Material

Table S1. Main characteristics of patients starting FreeStyle Libre system from August 1st 2017

	Type 1 diabetes	Type 2 diabetes	Total
Number of patients	33 165 (44.8%)	40 846 (55.2%)	74 011 (100%)
Age			
Mean (SD)	36.6 (19.4)	59.3 (15.4)	49.1 (20.7)
Median / Min / Max	35.0 / 1.0 / 97.0	62.0 / 18.0 / 99.0	52.0 / 1.0 / 99.0
Quartile 25 / Quartile 75	19.0 / 51.0	51.0 / 70.0	33.0 / 66.0
Age (by class)			
< 8 yrs	1 049 (3.2%)		1 049 (1.4%)
[8-15] yrs	3 709 (11.2%)		3 709 (5.0%)
[16-25] yrs	6 109 (18.4%)	1 316 (3.2%)	7 425 (10.0%)
[26-45] yrs	10 610 (32.0%)	5 485 (13.4%)	16 095 (21.7%)
[46-65] yrs	8 442 (25.5%)	16 897 (41.4%)	25 339 (34.2%)
[66-75] yrs	2 405 (7.3%)	11 141 (27.3%)	13 546 (18.3%)
>75 yrs	841 (2.5%)	6 007 (14.7%)	6 848 (9.3%)
Gender			
Male	17 365 (52.4%)	23 097 (56.5%)	40 462 (54.7%)
Female	15 800 (47.6%)	17 749 (43.5%)	33 549 (45.3%)
At least one reimbursement covered by the			
special assurance for deprived people			
No	29 021 (87.5%)	36 567 (89.5%)	65 588 (88.6%)
Yes	4 144 (12.5%)	4 279 (10.5%)	8 423 (11.4%)
Diabetes treatment in the 6 months before			
starting the FreeStyle Libre system			
Non-insulin diabetes treatment	66 (0.2%)	1 873 (4.6%)	1 939 (2.6%)
Insulin only	28 530 (86.0%)	19 323 (47.3%)	47 853 (64.7%)
Insulin + Non-insulin diabetes treatment	2 439 (7.4%)	18 429 (45.1%)	20 868 (28.2%)
ND	2 130 (6.4%)	1 221 (3.0%)	3 351 (4.5%)
Treatment Scheme in the 6 months before			
starting the FreeStyle Libre system			
Pump	10 967 (33.1%)	7 626 (18.7%)	18 593 (25.1%)
MDI	19 675 (59.3%)	27 153 (66.5%)	46 828 (63.3%)
Basal insulin scheme		3 077 (7.5%)	3 077 (4.2%)
Non-insulin diabetes treatment		1 839 (4.5%)	1 839 (2.5%)
ND	2 523 (7.6%)	1 151 (2.8%)	3 674 (5,0%)

Abbreviations: MDI: ND: Oral Anti-diabetic Drugs

Table S2. Number of acute diabetes complications per 1,000 patient years 12 months before and after starting FreeStyle Libre system

	Nature of acute diabetes complication	12 months before FreeStyle Libre initiation*	12 months after FreeStyle Libre initiation*	Change in number of events*
Type 1 diabetes (n=33,165)	Hospitalization for hypoglycemia	7.1	6.8	-0.3
	Hospitalization for coma	2.8	1.7	-1.1
	Hospitalization for DKA	63.9	29.3	-34.6
	Hospitalization for hyperglycemia	1.5	1.7	+0.2
	Hospitalization for at least one acute event	65.4	33.6	-31.8
Type 2 diabetes (n=40,846)	Hospitalization for hypoglycemia	7.6	6.8	-0.8
	Hospitalization for coma	2.5	1.7	-0.8
	Hospitalization for DKA	19.8	11.2	-8.6
	Hospitalization for hyperglycemia	1.2	0.9	-0.3
	Hospitalization for at least one acute event	27.5	16.8	-10.7
Total (n=74,011)	Hospitalization for hypoglycemia	7.3	6.8	-0.5
	Hospitalization for coma	2.6	1.7	-0.9
	Hospitalization for DKA	39.5	19.3	-20.2
	Hospitalization for hyperglycemia	1.4	1.3	-0.1
	Hospitalization for at least one acute event	44.5	24.3	-20.2

^{*} Data are number of events per 1,000 patient years in the 12 months before and after first prescription of FreeStyle Libre sensors.

Abbreviations : DKA, diabetic ketoacidosis

Table S3. Number of patients with acute diabetes complications 12 months before and after starting FreeStyle Libre system according to age and gender

		Number of male patients (%)		Number of female patients (%)		
		12 months before	12 months after	12 months before	12 months after	
	At least one	FreeStyle Libre	FreeStyle Libre	FreeStyle Libre	FreeStyle Libre	
Age (years)	hospitalization for:	initiation	initiation	initiation	initiation	
	Hypoglycemia	48 (0.78%)	54 (0.87%)	54 (0.90%)	52 (0.87%)	
<25	Coma	22 (0.36%)	11 (0.18%)	17 (0.28%)	16 (0.27%)	
<25	DKA	657 (10.64%)	264 (4.27%)	703 (11.70%)	313 (5.21%)	
	Hyperglycemia	17 (0.28%)	17 (0.28%)	19 (0.32%)	27 (0.45%)	
	At least one acute event	724 (11.72%)	333 (5.39%)	776 (12.92%)	393 (6.54%)	
	Hypoglycemia	60 (0.75%)	61 (0.76%)	36 (0.45%)	52 (0.64%)	
25-45	Coma	23 (0.29%)	18 (0.22%)	17 (0.21%)	8 (0.10%)	
25-45	DKA	333 (4.15%)	134 (1.67%)	289 (3.58%)	179 (2.22%)	
	Hyperglycemia	12 (0.15%)	11 (0.14%)	18 (0.22%)	9 (0.11%)	
	At least one acute event	416 (5.19%)	215 (2.68%)	345 (4.27%)	241 (2.99%)	
	Hypoglycemia	93 (0.64%)	82 (0.57%)	70 (0.64%)	57 (0.52%)	
46-65	Coma	40 (0.28%)	23 (0.16%)	20 (0.18%)	14 (0.13%)	
40-03	DKA	230 (1.59%)	94 (0.65%)	172 (1.58%)	87 (0.80%)	
	Hyperglycemia	10 (0.07%)	8 (0.26%)	8 (0.07%)	5 (0.05%)	
	At least one acute event	363 (2.51%)	201 (1.39%)	262 (2.40%)	157 (1.44%)	
	Hypoglycemia	48 (0.59%)	33 (0.41%)	28 (0.52%)	27 (0.50%)	
66-75	Coma	15 (0.18%)	13 (0.16%)	12 (0.22%)	3 (0.06%)	
00-75	DKA	52 (0.64%)	19 (0.23%)	32 (0.59%)	14 (0.26%)	
	Hyperglycemia	3 (0.04%)	2 (0.02%)	5 (0.09%)	3 (0.06%)	
	At least one acute event	116 (1.43%)	67 (0.82%)	74 (1.37%)	47 (0.87%)	
	Hypoglycemia	40 (1.08%)	27 (0.73%)	23 (0.73%)	23 (0.73%)	
	Coma	9 (0.24%)	7 (0.19%)	10 (0.32%)	6 (0.19%)	
≥75	DKA	17 (0.46%)	12 (0.33%)	53 (0.73%)	12 (0.38%)	
	Hyperglycemia	5 (0.14%)	2 (0.05%)	3 (0.10%)	3 (0.10%)	
	At least one acute event	69 (1.87%)	45 (1.22%)	59 (1.87%)	41 (1.30%)	

^{*} Data are number (%) of patients with at least one hospitalization in the 12 months before and after first prescription of FreeStyle Libre sensors.

Abbreviations: DKA, diabetic ketoacidosis

Table S4. Frequency of acute diabetes complications according to the period of time after starting the FreeStyle Libre system

(a) 3 months

	Cumulative number of days	Hypoglycemia	Coma	DKA	Hyperglycemia	At least one acute event
Type 1 diabetes	2 983 364	8.56	1.96	29.00	1.96	39.40
Type 2 diabetes	3 665 666	7.97	2.39	12.15	0.80	20.51
Total	6 649 030	8.23	2.20	19.71	1.32	28.98

(b) 6 months

	Cumulative number of days	Hypoglycemia	Coma	DKA	Hyperglycemia	At least one acute event
Type 1 diabetes	5 964 346	7.16	1.77	28.76	1.71	35.92
Type 2 diabetes	7 305 430	7.54	2.10	11.24	0.70	18.49
Total	13 269 776	7.37	1.95	19.12	1.16	26.32

(c) 12 months

	Cumulative number of days	Hypoglycemia	Coma	DKA	Hyperglycemia	At least one acute event
Type 1 diabetes	12 086 332	6.86	1.75	29.38	1.69	33.67
Type 2 diabetes	14 708 250	6.87	1.71	11.39	0.92	17.05
Total	26 794 582	6.87	1.73	19.51	1.27	24.55

Data are frequency of hospitalization for diabetes acute events per 1,000 patients years over 3, 6 and 12 months after starting the FreeStyle Libre system.

Table S5. Number of patients with acute diabetes complications 12 months before and after starting FreeStyle Libre for users on MDI and CSII therapy

		Number of patients (%)		
Insulin therapy	At least one hospitalization for:	12 months before FreeStyle Libre initiation	12 months after FreeStyle Libre initiation	
	Hypoglycemia	108 (0.59%)	105 (0.57%)	
	Coma	33 (0.18%)	27 (0.15%)	
CSII (n=18,282)	DKA	471 (2.58%)	329 (1.8%)	
(11–10,202)	Hyperglycemia	28 (0.15%)	20 (0.11%)	
	At least one acute event	624 (3.41%)	474 (2.59%)	
	Hypoglycemia	317 (0.74%)	282 (0.66%)	
	Coma	105 (0.24%)	65 (0.15%)	
MDI (n=43.041)	DKA	1243 (2.89%)	568 (1.32%)	
(n=43,041)	Hyperglycemia	41 (0.10%)	49 (0.11%)	
	At least one acute event	1657 (3.85%)	919 (2.14%)	

^{*} Data are number of events and % of patients with at least one hospitalization in the 12 months before and after first prescription of FreeStyle Libre sensors.

Abbreviations: DKA, diabetic ketoacidosis; Multiple daily insulin injections; CSII, Continuous subcutaneous insulin infusion

Table S6. Persistence with the FreeStyle Libre at 12 months after first use segregated by SMBG test strip acquisition and treatment with MDI or CSII

	Persistence with FreeStyle Libre (% of users)*				
SMBG strip				Number of	
use	All users	On MDI	On CSII	patients	
0 strips	97.3% (95% CI 97.1, 97.6)	97.4% (95% CI 97.1, 97.7)	96.9% (95% CI 96.2, 97.5)	19,396	
1-3 strips	98.0% (95% CI 97.8, 98.2)	97.9% (95% CI 97.6, 98.1)	97.9% (95% CI 97.4, 98.3)	17,682	
4-5 strips	98.7% (95% CI 98.5, 98.8)	98.8% (95% CI 98.6, 99.0)	98.6% (95% CI 98.2, 98.8)	21,374	
>5 strips	98.5% (95% CI 98.3, 98.7)	98.4% (95% CI 98.1 98.6)	98.8% (95% CI 98.5, 99.1)	15,559	
Total	98.1% (95% CI 98.0-98.2)	98.2% (95% CI 98.0-98.3)	98.3% (95% CI 98.1-98.4)	74,011	

^{*} Data are % of patients (95% Confidence Interval) still receiving delivery of FreeStyle Libre sensors 12 months after their first prescription and delivery .

Abbreviations: MDI, Multiple daily insulin injections; CSII, Continuous subcutaneous insulin infusion; SMBG, Self monitored blood glucose